AddLife AB (publ)

$ 155.60 -0.95 %

AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and research organizations (such as colleges and universities), and key players within the food and pharmaceutical industries. The firm's operations are divided into two distinct divisions: Labtech and Medtech. The Labtech segment provides a comprehensive array of products, integrated solutions, and expert services, focusing on diagnostics, biomedical research, and general laboratory requirements. This encompasses specialized instruments for areas like haematology, pathology, immediate diagnostic testing (point-of-care), cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, along with consumables and advanced analytical machinery. This division further offers vital support, maintenance, consultancy, and educational programs. Conversely, the Medtech segment concentrates on supplying a wide range of medical devices tailored for critical applications such as surgical procedures, respiratory support, intensive care, wound management, and enteral nutrition. It also develops products for fall prevention, welfare technology, and ear, nose, and throat conditions, in addition to offering specific assistive devices for bathrooms and specialized aids for children with disabilities. AddLife maintains a broad international presence, conducting business in its home country of Sweden, across the Nordics (Finland, Denmark, Norway), the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, other parts of Europe, and globally.

CEO: Fredrik Dalborg - https://www.add.life

Price objectif

-

Recommandation

-

DCF

$ 92.28

Loading data...

ALIF-B.ST vs S&P500

Loading data...

No data available.

Quick ratio

0.65

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

33.39

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

4.66

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

10.48 %

reflects reasonable profitability, showing good use of equity.

ROIC

5.16 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.90

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.85

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

8.80

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

16.02 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
2.51 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.19 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.37 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.